Daunomycin- and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery.
Seymour
L W
LW
Department of Biological Sciences, University of Keele, Staffordshire, U.K.
Duncan
R
R
Kopecková
P
P
Kopecek
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D055598:Chemical Phenomena; D002621:Chemistry; D003630:Daunorubicin / Q000627:therapeutic use / Q000633:toxicity*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D004337:Drug Carriers; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D011109:Polymethacrylic Acids / Q000627:therapeutic use / Q000633:toxicity*
D000970:Antineoplastic Agents; D004337:Drug Carriers; D011109:Polymethacrylic Acids; C055174:daunomycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugate; C055176:doxorubicin-N-(2-hydroxypropyl)methacrylamide copolymer conjugate; D004317:Doxorubicin; D003630:Daunorubicin